NasdaqGS:PODDMedical Equipment
Insulet EVOLVE Trial Targets Type 2 Market As Shares Trade Below Targets
Insulet (NasdaqGS:PODD) has begun its pivotal EVOLVE study of a fully closed loop automated insulin delivery system for people with type 2 diabetes.
The first participant has been enrolled, marking an important step in testing this technology beyond the company’s existing Omnipod 5 offering.
The study focuses on expanding automated insulin delivery to a large and currently underserved segment of the diabetes population.
For investors watching Insulet at a share price of $151.28, the EVOLVE...